Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study - SAN DIEGO, CA / ...
SAN DIEGO, February 26, 2025--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing ...
SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of ...
SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained ...
On Monday, Revelation Biosciences Inc (NASDAQ:REVB) announced safety and biomarker data for its Phase 1 study (RVL-HV02). The primary endpoint to evaluate the safety and tolerability of escalating ...
(RTTNews) - Revelation Biosciences, Inc. (REVB), a clinical-stage life sciences company, announced on Monday that the FDA has accepted its Investigational New Drug (IND) application for Gemini, ...
SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback